NCT07298395RecruitingPhase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ENV-294 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Enveda Therapeutics32 sites in 1 country60 target enrollmentStarted: December 22, 2025Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Enrollment
- 60
- Locations
- 32
- Primary Endpoint
- To evaluate the efficacy of ENV-294 compared to placebo on severity and extent of atopic dermatitis (AD)
Study Overview
Brief Summary
The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis.
The main questions it will answer are:
- Is there an impact on the severity and area of atopic dermatitis when participants take ENV-294
- What medical problems do participants have when taking ENV-294
Participants will:
- Take drug ENV-294 or a placebo once every day for 12 weeks
- Visit the clinic every 2 to 4 weeks for checkups and tests
- Keep a diary of their symptoms and when they took their study drug
- Return to the clinic for the final study visit at approximately week 16
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Have chronic atopic dermatitis that was diagnosed at least 12 months prior to the first study visit
- •Have moderate-to-severe AD at screening and baseline as defined by the following criteria:
- •A vIGA score of 3 (moderate) or 4 (severe)
- •EASI score of ≥16
- •PP-NRS score of ≥4
- •Have had either a poor response or intolerance to topical treatments for atopic dermatitis (such as corticosteroids) within the past 6 months
- •Use a bland moisturizer at least daily
Exclusion Criteria
- •Current or recurrent medical conditions that could affect the study drug or study assessments
- •Any illness that could impact participant safety or active infections
- •Ongoing skin condition or large tattoos that would interfere with clinical assessment
- •Clinically significant skin infection requiring treatment
- •Clinically significant abnormal laboratory assessments at screening
Arms & Interventions
Placebo Arm
Placebo Comparator
A placebo will be administered to those participants randomized to the placebo arm.
Intervention: Placebo (Drug)
ENV-294 Treatment Arm
Experimental
ENV-294 will be administered to those participants randomized to the treatment arm.
Intervention: ENV-294 (Drug)
Outcomes
Primary Outcomes
To evaluate the efficacy of ENV-294 compared to placebo on severity and extent of atopic dermatitis (AD)
Time Frame: Baseline to Week 12
The effectiveness of ENV-294 compared with placebo will be assessed by the percent change in Eczema Area and Severity Index (EASI) score from the start of the study (Baseline) to Week 12 (Day 85). The EASI score measures the extent and severity of atopic dermatitis, with higher scores indicating more severe disease.
Secondary Outcomes
- Incidence and Severity of Adverse Events(Baseline to Week 12)
- EASI-75 Response(Baseline to Week 12)
- vIGA Response(Baseline to Week 12)
- Patient-Reported Outcomes(Baseline to Week 12)
- Pharmacokinetics of ENV-294(Baseline to Week 12)
Investigators
Study Sites (32)
Loading locations...
Similar Trials
Recruiting
Phase 2
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLCNon-squamous Non-small Cell Lung CancerNCT07264816Sichuan Baili Pharmaceutical Co., Ltd.80
Not yet recruiting
Phase 3
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）Overweight or ObesityNCT07274137MindRank AI Ltd738
Recruiting
Phase 2
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)Ulcerative ColitisNCT07265570InSilico Medicine Hong Kong Limited80
Not yet recruiting
Phase 2
CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate CancerProstate Cancer (Adenocarcinoma)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Metastatic Prostate CancerNCT07268794Fudan University112
Recruiting
Phase 2
Topical Ketotifen 0.25% for Secondary VestibulodyniaProvoked VestibulodyniaSecondary Provoked VestibulodyniaNeuroproliferative VestibulodyniaVulvodyniaVulvary Pain DisordersMast Cell-mediated NeuroinflammationInstertional DyspareuniaNCT07257029Center for Vulvovaginal Disorders54